Merck Announces $6.7 Billion Cash Acquisition of Cancer Biotechnology Company Terns
March 26, 2026
Source: drugdu
30
On March 25 local time, US pharmaceutical giant Merck...The company announced that it has reached a $6.7 billion all-cash deal to acquire cancer biotechnology company Terns Pharmaceuticals in order to obtain one of its promising leukemia treatments.
Under the terms of the agreement, Merck will acquire Terns for $53 per share, a total transaction valued at approximately $6.7 billion, including Terns' cash holdings. After deducting the acquired company's cash holdings, the net consideration is approximately $5.7 billion. Terns is headquartered in Fox, California.Terns, based in Tet City, has been dedicated to developing oral medications for the treatment of cancer, obesity, and metabolic liver diseases. Its core product is TERN-701, an oral medication used to treat chronic myeloid leukemia.
https://finance.eastmoney.com/a/202603263685113817.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- West Point Pharmaceuticals’ application for marketing approval of ferric protein succinate, a drug for treating iron deficiency anemia, has been approved March 26, 2026
- “Human Interferon Alpha-1b Inhalation Solution” to be Included in Breakthrough Therapy Program March 26, 2026
- Another MNC is increasing its investment in China March 26, 2026
- Federal Pharmaceuticals’ subsidiary innovative drug UBT251 has achieved success in Phase II clinical trials March 26, 2026
- Grand Pharmaceutical’s strategic partner Telix’s first-in-class rADC in a multicenter international Phase III trial has made positive progress March 26, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
